Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial

Pallavi Madhiraju- July 19, 2023 0

Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer's Association International Conference (AAIC), indicating that ... Read More

Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt

pharmanewsdaily- August 19, 2020 0

Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed ... Read More

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

pharmanewsdaily- May 9, 2020 0

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and ... Read More

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

pharmanewsdaily- December 12, 2019 0

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More